A GLP-1 maintenance dose is the weekly dose you stay on after the escalation phase, once the medication is working and you tolerate it. For Wegovy (semaglutide) the labeled maintenance dose is 2.4 mg or 1.7 mg once a week. For Zepbound (tirzepatide) it is 5 mg, 10 mg or 15 mg once a week. Whether you can go lower after you reach your goal weight is a different question, and the evidence is thinner than most articles admit. This guide separates what is labeled, what has been tested in trials, and what clinicians do in practice.
TL;DR
- “Maintenance dose” has two meanings: the labeled dose you reach at the end of escalation, and a lower dose some people move to after hitting a goal weight.
- FDA labels set Wegovy maintenance at 2.4 mg (recommended) or 1.7 mg weekly, and Zepbound maintenance at 5, 10 or 15 mg weekly.
- In a 2026 tirzepatide trial, people who dropped to 5 mg kept more weight off than those switched to placebo, but less than those who stayed on their top dose.
- Stepping down or stretching out injections is common clinical practice, not an established guideline, so it should be designed with your prescriber.
- Current U.S. expert guidance favors continuing medication in the maintenance phase rather than routinely stopping.
Table of Contents
- What “maintenance dose” actually means
- FDA-labeled maintenance doses
- How a clinician picks your dose
- What the evidence says about going lower
- Stepping down versus stretching out
- Should you stop altogether?
- What else holds weight off
- Our perspective
- Getting a plan you can maintain
- FAQ
- Sources
What “maintenance dose” actually means
Search results use the phrase loosely, which causes real confusion. There are two separate ideas.
The labeled maintenance dose. Every GLP-1 used for weight management starts low and rises in steps. The dose at the top of that ladder, the one you stay on, is the maintenance dose in the FDA’s sense. It is reached while you are still losing weight, not after you finish.
The goal-weight maintenance dose. Once you have lost what you set out to lose, some clinicians and patients ask whether a lower dose, or less frequent dosing, can hold the result. This is the question most readers mean. There is no single answer, and it depends on your response, your side effects and your history.
Keeping the two apart prevents the most common mistake: assuming there is a standard “lower maintenance dose” that every patient graduates to.
FDA-labeled maintenance doses
Semaglutide (Wegovy)
The Wegovy label starts treatment at 0.25 mg once weekly for four weeks, then steps up every four weeks through 0.5 mg, 1 mg and 1.7 mg. The maintenance dose is 2.4 mg once weekly (recommended) or 1.7 mg once weekly, and the label tells prescribers to consider treatment response and tolerability when choosing between them. If a dose is not tolerated during escalation, the label allows delaying the next step by four weeks.
So 1.7 mg is not a failure or a downgrade. It is a labeled maintenance dose. For a walkthrough of the steps leading there, see our Wegovy dosing schedule and semaglutide dose escalation guide.
Tirzepatide (Zepbound)
The Zepbound label begins at 2.5 mg once weekly for four weeks. That starting dose is for initiation only. Doses then rise in 2.5 mg increments, and only after at least four weeks on the current dose. The maintenance doses for weight reduction and long-term maintenance are 5 mg, 10 mg or 15 mg once weekly, with 15 mg as the maximum. If a maintenance dose is not tolerated, the label says a lower maintenance dose may be considered.
Our Zepbound dosage schedule and tirzepatide dosing schedule pages cover the timeline in detail.
Quick comparison
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Starting dose | 0.25 mg weekly | 2.5 mg weekly (initiation only) |
| Time at each step | 4 weeks | At least 4 weeks |
| Labeled maintenance dose | 2.4 mg (recommended) or 1.7 mg weekly | 5 mg, 10 mg or 15 mg weekly |
| Maximum | 2.4 mg weekly | 15 mg weekly |
| If not tolerated | Delay escalation by 4 weeks | Consider a lower maintenance dose |
How a clinician picks your dose
The label itself is the best guide to the logic: response and tolerability decide. In practice that means a prescriber looks at a few things at each visit.
- How much weight you have lost so far and whether the curve is flattening.
- Side effects. Nausea, constipation or fatigue that persist at a given dose are a reason to hold or step back. Our guide to Zepbound side effects explains what to report and when.
- Other conditions and medications. Blood sugar, blood pressure and other drugs all matter. If you take metformin, see semaglutide with metformin.
- Your goal. Losing more, holding steady and managing a health condition can call for different doses.
A 2026 Lancet commentary argues for exactly this adaptive, response-guided approach, because a fixed lower tirzepatide dose is adequate for some people and insufficient for others.
What the evidence says about going lower
The strongest data on reducing a dose for maintenance come from the 2026 SURMOUNT-MAINTAIN trial of tirzepatide. After a 60-week weight-loss period, participants entered a further 52-week maintenance period and were assigned to one of three paths: continued maximum-tolerated tirzepatide, a reduction to 5 mg, or placebo.
At week 112, model-based body-weight change from baseline was:
| Maintenance arm | Change in body weight at week 112 |
|---|---|
| Maximum-tolerated tirzepatide | −21.9% |
| Reduced to 5 mg | −16.6% |
| Placebo | −9.9% |
Three things stand out.
- Staying on the higher dose preserved the most. Continuing at the maximum tolerated dose gave the best result.
- Dropping to 5 mg still beat stopping. The Lancet commentary says reducing to 5 mg protected against regain better than withdrawal.
- Individual responses varied widely. Among participants who had reached a plateau, 5 mg preserved a mean 67.9% of the weight lost in the initial period, and 42.4% kept at least 80% of it, according to the same commentary. In other words, a little under half held nearly all their loss on the lower dose, and the rest held less.
The practical reading: a lower dose is a reasonable option for some people, but nobody can promise in advance that it will work for you. That is why monitoring in the months after a step-down matters more than the step itself.
Stepping down versus stretching out
Two strategies come up repeatedly in clinic conversations and online forums.
- Stepping down: moving to a lower weekly dose, for example from the top dose to a lower labeled dose.
- Stretching out: keeping the dose but injecting less often, such as every ten days instead of every seven.
Stepping down to a labeled dose has a clear footing in the prescribing information, since both labels name lower maintenance doses. Stretching intervals is different. A 2024 review of licensed, practised and evidenced maintenance dosing states that step-down and interval-spacing strategies are described by clinicians but are not established guideline recommendations and lack trial support. It advises that a clinician design any individualized plan, and that these practices not be presented as evidence-based standard care.
We agree with that framing. If you read that a “standard” maintenance dose is a quarter of your current dose, or that you can simply inject every other week, treat it as someone’s experience, not as a rule. Changing the schedule on your own, particularly with medication that has side effects when restarted at high doses, is how people end up with avoidable nausea and lost progress.
Should you stop altogether?
Most current evidence points toward continuing in some form. The SURMOUNT-MAINTAIN investigators conclude that long-term treatment is often necessary to maintain bodyweight reduction and the associated cardiometabolic benefits. The joint TOS/OMA/OAC U.S. expert guidance statement recommends continuing obesity medication during the weight-maintenance phase rather than routinely stopping it, and describes this as a strong recommendation with moderate certainty.
The placebo arm above is the clearest picture of what stopping can look like: the group switched to placebo ended at −9.9% from baseline, against −21.9% for those who continued. That does not mean every person who stops regains everything. It means that obesity behaves like a chronic condition for many people, and the medication works while you take it.
If you do need to stop, because of cost, side effects, pregnancy planning or a medical reason, tell your prescriber first. Ask about a stepped plan, a follow-up schedule for weight and blood pressure, and what you will do if weight starts to climb. Your appetite will probably return as the drug wears off, so decide in advance how you will handle it.
What else holds weight off
Medication is one part of maintenance. The habits that kept you full and moving during treatment are the same ones that protect the result at a lower dose or after a change.
- Protein and strength training help preserve muscle as you lose fat and as the dose changes.
- Regular weigh-ins (weekly, same conditions) let you catch a 3 to 5 pound drift early, when it is easy to correct.
- A stocked kitchen removes daily decisions. A weight loss grocery list organized aisle by aisle makes it easier to keep buying the foods that fit smaller appetites.
- Regular check-ins with the person who prescribes your medication, since dose decisions should follow your data, not a calendar.
Our perspective
We see the same pattern again and again: people treat the end of escalation as the finish line, and the first six months after goal weight as an afterthought. We think that is backwards. Reaching the weight is the easy part to measure. Holding it is the part that decides whether treatment changed your life.
So we do not push a single “maintenance dose.” Your metabolism, your side effects and your history are different from the next patient’s, and the trial data above show how different the responses to a lower dose can be. Our approach is to match the dose to the person, review it regularly, and keep support open, which is why our program includes free provider visits and unlimited guidance rather than charging for each check-in. If your plan changes, you should be able to ask a question the same day, not wait for a billing cycle.
We also think honesty matters here. Lower-dose and spaced-out schedules are worth discussing, but we will tell you when the evidence is thin, and we will not dress up a preference as a protocol.
— Bryan
Getting a plan you can maintain
If you are mid-treatment, the sensible next step is to bring three numbers to your next visit: your starting weight, your current weight and your current dose, along with how you feel on it. That is enough for a clinician to say whether you are still losing, plateaued, or ready to discuss maintenance.
If you are considering starting, Legacy Meds offers online provider assessment and GLP-1 prescription programs with no membership fees and no insurance required. Pricing starts at $159 for GLP-1 injections (one-off) and the semaglutide program is listed from $159 per month. Wegovy and Zepbound options are also available, and you can see the current options on our treatment page. Prescribing depends on the provider’s assessment. If you are weighing medications, our comparison of semaglutide versus tirzepatide and our guide to switching GLP-1 medications are good places to start. Read our GLP-1 medication safety information before you begin.
FAQ
What is the maintenance dose of semaglutide for weight loss?
For Wegovy, the FDA label lists 2.4 mg once weekly as the recommended maintenance dose, with 1.7 mg once weekly as an alternative. The prescriber chooses based on your response and tolerability. Lower doses than these are not labeled maintenance doses for weight management.
What is the maintenance dose of tirzepatide?
For Zepbound, the labeled maintenance doses are 5 mg, 10 mg or 15 mg once weekly. The 2.5 mg dose is only for starting treatment, and 15 mg is the maximum. If you cannot tolerate a maintenance dose, the label says a lower one may be considered.
Can I lower my GLP-1 dose once I reach my goal weight?
Sometimes, with your prescriber. In the 2026 SURMOUNT-MAINTAIN trial, people reduced to 5 mg of tirzepatide kept more weight off than those switched to placebo, though less than those who continued the top dose. Responses varied, so the change should come with follow-up.
Can I inject less often to maintain weight?
Some clinicians use longer intervals, but this is not an established guideline and lacks trial support. Do not stretch your schedule on your own. Ask your prescriber whether a lower labeled dose is a better option for you.
How long will I need to stay on a GLP-1?
For many people, long-term. Trial investigators conclude that long-term treatment is often necessary to keep weight and cardiometabolic benefits, and U.S. expert guidance recommends continuing medication in the maintenance phase. Your duration should be set with your prescriber based on your health and goals.
Sources
- FDA Wegovy prescribing information
- FDA Zepbound prescribing information
- SURMOUNT-MAINTAIN: tirzepatide for maintenance of bodyweight reduction (The Lancet)
- Personalising maintenance after tirzepatide weight loss (The Lancet commentary)
- Joint TOS/OMA/OAC expert guidance statement on pharmacological management of adults with overweight or obesity
- Maintenance dosing: what is licensed, what is practised, and what is evidenced